Prime Medicine, Inc. (NYSE:PRME - Free Report) - Stock analysts at Chardan Capital issued their FY2025 earnings estimates for Prime Medicine in a report released on Monday, March 10th. Chardan Capital analyst G. Livshits forecasts that the company will earn ($1.25) per share for the year. Chardan Capital has a "Buy" rating and a $15.00 price objective on the stock. The consensus estimate for Prime Medicine's current full-year earnings is ($1.68) per share.
Prime Medicine (NYSE:PRME - Get Free Report) last posted its quarterly earnings data on Friday, March 7th. The company reported ($1.65) earnings per share for the quarter. During the same period in the prior year, the business posted ($2.18) EPS.
A number of other equities research analysts have also recently commented on PRME. HC Wainwright reiterated a "buy" rating and issued a $10.00 target price on shares of Prime Medicine in a research report on Monday, March 3rd. Wedbush reiterated an "outperform" rating and issued a $12.00 target price on shares of Prime Medicine in a research report on Friday, February 28th. StockNews.com upgraded shares of Prime Medicine to a "sell" rating in a research report on Tuesday, February 11th. Citizens Jmp upgraded shares of Prime Medicine to a "strong-buy" rating in a research report on Tuesday, December 10th. Finally, JMP Securities initiated coverage on shares of Prime Medicine in a research report on Tuesday, December 10th. They issued an "outperform" rating and a $10.00 target price for the company. One research analyst has rated the stock with a sell rating, nine have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $13.13.
View Our Latest Stock Analysis on PRME
Prime Medicine Trading Down 2.2 %
NYSE:PRME traded down $0.04 during trading hours on Thursday, reaching $1.75. 1,005,170 shares of the company were exchanged, compared to its average volume of 1,089,175. The stock's 50-day moving average is $2.68 and its 200-day moving average is $3.26. The firm has a market cap of $229.53 million, a PE ratio of -0.85 and a beta of 1.85. Prime Medicine has a twelve month low of $1.71 and a twelve month high of $8.27.
Institutional Investors Weigh In On Prime Medicine
A number of hedge funds have recently modified their holdings of the company. GSA Capital Partners LLP purchased a new position in Prime Medicine during the third quarter worth about $383,000. Intech Investment Management LLC purchased a new position in Prime Medicine during the third quarter worth about $55,000. Corsair Capital Management L.P. purchased a new position in Prime Medicine during the third quarter worth about $77,000. PEAK6 Investments LLC boosted its stake in Prime Medicine by 32.4% during the third quarter. PEAK6 Investments LLC now owns 45,013 shares of the company's stock worth $174,000 after buying an additional 11,013 shares during the period. Finally, Walleye Capital LLC purchased a new position in Prime Medicine during the third quarter worth about $419,000. Hedge funds and other institutional investors own 70.37% of the company's stock.
About Prime Medicine
(
Get Free Report)
Prime Medicine, Inc, a biotechnology company, delivers genetic therapies to address the spectrum of diseases by deploying gene editing technology. The company offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence.
Featured Stories
Before you consider Prime Medicine, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Prime Medicine wasn't on the list.
While Prime Medicine currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
